Q4 2024 Mineralys Therapeutics Inc Earnings Call Transcript
Key Points
- Mineralys Therapeutics Inc (MLYS) is on track to announce top-line data from its pivotal Advance-HTN trial in March and Launch-HTN trial in the mid-first half of 2025.
- The company has completed enrollment in the Explore-CKD Phase 2 trial, which evaluates lorundrostat for hypertension in patients with chronic kidney disease.
- Mineralys Therapeutics Inc (MLYS) has a strong cash position, with $198.2 million in cash equivalents and investments as of December 31, 2024, sufficient to fund operations through Q1 2026.
- The company is exploring innovative approaches, such as continuous blood pressure monitoring during sleep, in its Explore-OSA Phase 2 trial for obstructive sleep apnea.
- Mineralys Therapeutics Inc (MLYS) has received positive feedback from payers regarding the potential market positioning of lorundrostat, particularly in resistant hypertension.
- Mineralys Therapeutics Inc (MLYS) reported a significant increase in net loss for 2024, amounting to $177.8 million compared to $71.9 million in 2023.
- Research and development expenses have more than doubled, reaching $168.6 million in 2024, driven by increased clinical and pre-clinical costs.
- The company faces challenges in ensuring compliance with 24-hour ambulatory blood pressure monitoring devices, which could affect trial data quality.
- There is uncertainty regarding the extrapolation of Phase 2 trial results to larger pivotal studies due to small sample sizes in earlier trials.
- Mineralys Therapeutics Inc (MLYS) anticipates potential challenges in differentiating lorundrostat from existing mineralocorticoid receptor antagonists, particularly regarding efficacy and safety profiles.
Good morning, ladies and gentlemen, and welcome to the Mineralys fourth quarter and fourth year 2024 earnings conference call. (operator instructions) Also note that this call is being recorded on Wednesday, February 12, 2025. And I would like to turn the conference over to Dan Ferry of Lifesci Advisors. Please go ahead, sir.
Thank you, operator.
I would like to welcome everyone joining us today for our fourth quarter and full year 2024 conference call. Earlier this morning, we issued a press release providing our fourth quarter and full year 2024 financial results and business updates. A replay of today's call will be available on the investors section of our website approximately one hour after its completion. After our prepared remarks, we will open up the call for Q&A.
Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. Actual results could differ materially from those stated or implied by
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
